Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
16 Maio 2014 - 1:05PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
SEC
File Number: 001-13467
(Check
One):
|
[ ]
Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR [ ]
Form N-CSR
|
|
|
|
For
Period Ended:
March 31, 2014
|
|
|
|
[ ]
Transition Report on Form 10-K
|
|
|
|
[ ]
Transition Report on Form 20-F
|
|
|
|
[ ]
Transition Report on Form 11-K
|
|
|
|
[ ]
Transition Report on Form 10-Q
|
|
|
|
[ ]
Transition Report on Form N-SAR
|
|
|
|
For
the Transition Period Ended: ________________________
|
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
If
the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:
______________________________________________________
PART
I -- REGISTRANT INFORMATION
TARGETED
MEDICAL PHARMA, INC.
Full
name of registrant:
Former
name if applicable:
2980
Beverly Glen Circle, Suite 301
Address of principal executive office (Street and number):
Los
Angeles, CA 90077
City,
state and zip code
PART
II -- RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if appropriate.)
|
(a)
|
The
reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
|
|
|
[X]
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof,
will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or
transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed
due date; and
|
|
|
|
|
(c)
|
The
accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART
III -- NARRATIVE
State
below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report or portion thereof,
could not be filed within the prescribed time period.
Targeted
Medical Pharma, Inc. (the “Company”) was unable to file its Quarterly Report on Form 10-Q for the fiscal quarter ended
March 31, 2014 on a timely basis due to additional time needed for compilation and review to insure adequate disclosure of certain
information required to be included in the Form 10-Q. The Company expects to file its Form 10-Q within the additional time allowed
by this report.
PART
IV -- OTHER INFORMATION
(1)
|
Name
and telephone number of person to contact in regard to this notification
|
|
William
Horne
|
|
(301)
474-9809
|
|
(Name)
|
|
(Area
Code) (Telephone Number)
|
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the
Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required
to file such report(s) been filed? If the answer is no, identify report(s).
|
|
|
|
[X]
Yes [ ] No
|
|
|
(3)
|
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year
will be reflected by the earnings statements to be included in the subject report or portion thereof?
|
|
|
|
[X]
Yes [ ] No
|
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.
Targeted
Medical Pharma, Inc. (the
“Company”
) anticipates that its revenue for the three months ended March 31,
2014 will be approximately $1.8 million, significantly less than its revenue for the three months ended March 31, 2013 of $2.8
million. The decrease in revenue is primarily the result of a decrease in cash collections from the Company’s customers
that are accounted for pursuant to the cash method of accounting. The Company anticipates that its operating expenses will be
significantly less than the three months ended March 31, 2013 as a result of decreases in salary and general and administrative
expenses. The net loss for the three months ended March 31, 2014 is expected to be significantly more than the three months ended
March 31, 2013 primarily as a result of these factors.
A
reasonable estimate of the results cannot be made at this time due to the fact that the compilation, dissemination and review
of the information required to be presented in the Form 10-Q has not been completed.
Targeted
Medical Pharma, Inc.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
May 16, 2014
|
Targeted
Medical Pharma, Inc.
|
|
(Registrant)
|
|
|
|
/s/
William Horne
|
|
William
Horne
|
|
Chief
Financial Officer
|
ATTENTION
Intentional
misstatements or omissions of fact constitute Federal criminal violations. (See 18 U.S.C. 1001).
Targeted Medical Pharma (CE) (USOTC:TRGM)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Targeted Medical Pharma (CE) (USOTC:TRGM)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024